Header cover image

German (DAX) Biotech Industry Analysis

UpdatedJan 31, 2023
DataAggregated Company Financials
Companies12
  • 7D-2.1%
  • 3M3.4%
  • 1Y9.0%
  • YTD-3.7%

Over the last 7 days, the Biotech industry has dropped 2.1%, driven by Formycon declining 5.3%. Over the past 12 months, the industry was up 9.0%. As for the next few years, earnings are expected to grow by 55% per annum.

Industry Valuation and Performance

Has the German Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 31 Jan 2023€3.0b€611.9m-€53,407,435.0010.7x-55.7x4.9x
Thu, 29 Dec 2022€3.0b€611.9m-€53,407,435.0011.1x-56.2x4.9x
Sat, 26 Nov 2022€3.0b€611.8m-€48,604,435.0011.1x-62x4.9x
Mon, 24 Oct 2022€2.6b€627.4m-€129,805,157.006x-19.7x4.1x
Wed, 21 Sep 2022€2.6b€627.4m-€129,805,157.005.4x-20x4.1x
Fri, 19 Aug 2022€2.8b€605.7m-€150,021,513.006.3x-18.6x4.6x
Sun, 17 Jul 2022€3.4b€772.0m-€724,268,362.00n/a-4.6x4.4x
Tue, 14 Jun 2022€3.2b€768.8m-€724,082,241.00n/a-4.5x4.2x
Thu, 12 May 2022€3.2b€769.9m-€723,863,944.00n/a-4.4x4.1x
Sat, 09 Apr 2022€3.8b€808.9m-€704,269,813.00n/a-5.4x4.7x
Mon, 07 Mar 2022€3.4b€789.6m-€311,283,353.00n/a-11x4.3x
Wed, 02 Feb 2022€3.7b€789.6m-€311,283,353.00n/a-12x4.7x
Fri, 31 Dec 2021€4.1b€789.6m-€311,690,565.00n/a-13x5.1x
Sun, 28 Nov 2021€4.1b€789.6m-€311,690,565.00n/a-13.1x5.2x
Tue, 26 Oct 2021€4.5b€771.2m-€257,628,521.00n/a-17.5x5.8x
Thu, 23 Sep 2021€4.3b€764.0m-€156,817,446.001.3x-27.5x5.6x
Sat, 21 Aug 2021€4.2b€769.4m-€175,243,228.001.4x-24x5.5x
Sat, 05 Jun 2021€5.0b€742.3m-€215,931,793.001.3x-23x6.7x
Tue, 09 Mar 2021€5.7b€929.7m-€78,349,962.2327.9x-72.9x6.1x
Mon, 30 Nov 2020€5.4b€857.0m-€138,041,722.0268x-39.1x6.3x
Thu, 03 Sep 2020€6.2b€856.0m-€124,654,217.9532.8x-49.7x7.2x
Sun, 07 Jun 2020€6.1b€859.6m-€127,445,277.3225x-47.5x7x
Sat, 29 Feb 2020€5.1b€602.0m-€403,838,466.74n/a-12.7x8.5x
Price to Earnings Ratio

-14.9x


Total Market Cap: €6.0bTotal Earnings: -€402,351,766.74Total Revenue: €601.6mTotal Market Cap vs Earnings and Revenue0%0%0%
German Biotech Industry Price to Earnings3Y Average -31.7x202120222023
Current Industry PE
  • Investors are pessimistic on the German Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 5.7x is higher than the industry's current PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.

Industry Trends

Which industries have driven the changes within the German Healthcare industry?

DE Market0.26%
Healthcare0.31%
Biotech-2.10%
Biotech-2.10%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MOR MorphoSys€18.002.5%
+€15.0m
-36.3%PS2.5x
T5O bioXXmed€3.32130.6%
+€9.7m
-21.7%PS383.5x
PA8 Paion€0.7119.7%
+€8.3m
-47.4%PS1.8x
HPHA Heidelberg Pharma€5.122.0%
+€4.7m
18.9%PS13.8x
2INV 2invest€8.883.5%
+€1.7m
-31.7%PS17.4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

20B

€0.13

BioMark Diagnostics

7D

-3.1%

1Y

-18.6%

MOR

€18.00

MorphoSys

7D

2.5%

1Y

-36.3%

PA8

€0.71

Paion

7D

19.7%

1Y

-47.4%

MDG1

€2.11

Medigene

7D

-2.8%

1Y

-6.6%

ECX1

€1.40

Epigenomics

7D

-1.0%

1Y

-35.0%

FYB

€82.00

Formycon

7D

-5.3%

1Y

69.9%

PJ2N

€3.21

Liminal BioSciences

7D

-3.2%

1Y

-84.9%

HPHA

€5.12

Heidelberg Pharma

7D

2.0%

1Y

18.9%

T5O

€3.32

bioXXmed

7D

130.6%

1Y

-21.7%

2INV

€8.88

2invest

7D

3.5%

1Y

-31.7%